SCHEMBL2655153

SCHEMBL2655153

CCC(=O)Nc1nc2ccc(OC)nc2s1

nearest known ligand 0.56

Predicted protein targets (top 19)

geneUniProtsupporting neighboursconfidence
RAB9A P51151 11/20 0.56
NPC1 O15118 8/20 0.56
SMN1; SMN2 Q16637 8/20 0.56
KMT2A Q03164 3/20 0.51
MEN1 O00255 2/20 0.50
TSHR P16473 2/20 0.50
HSD17B10 Q99714 2/20 0.50
LMNA P02545 1/20 0.50
HPGD P15428 1/20 0.50
MAPT P10636 2/20 0.48
ABL1 P00519 1/20 0.47
ALDH1A1 P00352 4/20 0.46
TP53 P04637 3/20 0.46
CASP2 P42575 1/20 0.46
KDM4E B2RXH2 2/20 0.44
POLB P06746 2/20 0.44
CSNK1D P48730 1/20 0.44
HTT P42858 1/20 0.44
PDE10A Q9Y233 1/20 0.43

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL4915134 0.79 SCD (0.61) RAB9ANPC1SMN1; SMN2KMT2AMEN1
SCHEMBL24847460 0.78 KDM4E (0.52) RAB9ANPC1SMN1; SMN2KMT2AMEN1
SCHEMBL24847397 0.78 CCNE1 (0.52) SMN1; SMN2KMT2AMEN1TSHRLMNA
SCHEMBL4914811 0.78 SCD (0.66) RAB9ANPC1SMN1; SMN2KMT2AMEN1
SCHEMBL4921043 0.78 ALDH1A1 (0.55) RAB9ANPC1SMN1; SMN2KMT2AMEN1
SCHEMBL4918031 0.77 NPC1 (0.63) RAB9ANPC1SMN1; SMN2KMT2AMEN1
SCHEMBL4917530 0.77 KMT2A (0.57) RAB9ANPC1SMN1; SMN2KMT2AMEN1
SCHEMBL14243031 0.76 LCK (0.41) RAB9ANPC1SMN1; SMN2KMT2AMEN1
SCHEMBL4917961 0.76 ALDH1A1 (0.54) RAB9ANPC1SMN1; SMN2KMT2AMEN1
SCHEMBL4923647 0.76 RAB9A (0.64) RAB9ANPC1SMN1; SMN2KMT2AMEN1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-1735322-A1 SULFONAMIDE-THIAZOLPYRIDINE DERIVATIVES AS GLUCOKINASE ACTIVATORS USEFUL THE TREATMENT OF TYPE 2 DIABETES Novartis AG (CH) 2006-12-27 EP disclosed
WO-2005095418-A1 SULFONAMIDE-THIAZOLPYRIDINE DERIVATIVES AS GLUCOKINASE ACTIVATORS USEFUL THE TREATMENT OF TYPE 2 DIABETES NOVARTIS AG (CH) 2005-10-13 WO disclosed